Targeting the 8-oxodG Base Excision Repair Pathway for Cancer Therapy

Piscone, Anna; Gorini, Francesca; Ambrosio, Susanna; Noviello, Anna; Scala, Giovanni; Majello, Barbara; Amente, Stefano

doi:10.3390/cells14020112

Open AccessReview

Targeting the 8-oxodG Base Excision Repair Pathway for Cancer Therapy

by

Anna Piscone

^1,†,

Francesca Gorini

^1,†,

Susanna Ambrosio

²,

Anna Noviello

²,

Giovanni Scala

²,

Barbara Majello

²

and

Stefano Amente

^1,*

¹

Department of Molecular Medicine and Medical Biotechnologies, University of Naples ‘Federico II’, 80131 Naples, Italy

²

Department of Biology, University of Naples ‘Federico II’, 80138 Naples, Italy

^*

Author to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Cells 2025, 14(2), 112; https://doi.org/10.3390/cells14020112

Submission received: 20 December 2024 / Revised: 7 January 2025 / Accepted: 10 January 2025 / Published: 14 January 2025

(This article belongs to the Special Issue DNA Damage and Repair for Targeted Cancer Therapy)

Download

Browse Figures

Versions Notes

Abstract

Genomic integrity is critical for cellular homeostasis, preventing the accumulation of mutations that can drive diseases such as cancer. Among the mechanisms safeguarding genomic stability, the Base Excision Repair (BER) pathway plays a pivotal role in counteracting oxidative DNA damage caused by reactive oxygen species. Central to this pathway are enzymes like 8-oxoguanine glycosylase 1 (OGG1), which recognize and excise 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) lesions, thereby initiating a series of repair processes that restore DNA integrity. BER inhibitors have recently been identified as a promising approach in cancer therapy, increasing the sensitivity of cancer cells to radiotherapy and chemotherapy. By exploiting tumor-specific DNA repair dependencies and synthetic lethal interactions, these inhibitors could be used to selectively target cancer cells while sparing normal cells. This review provides a robust reference for scientific researchers, offering an updated perspective on small-molecule inhibitors targeting the 8-oxodG-BER pathway and highlighting their potential role in expanding cancer treatment strategies.

Keywords: BER; 8-oxodG; cancer therapy

Share and Cite

MDPI and ACS Style

Piscone, A.; Gorini, F.; Ambrosio, S.; Noviello, A.; Scala, G.; Majello, B.; Amente, S. Targeting the 8-oxodG Base Excision Repair Pathway for Cancer Therapy. Cells 2025, 14, 112. https://doi.org/10.3390/cells14020112

AMA Style

Piscone A, Gorini F, Ambrosio S, Noviello A, Scala G, Majello B, Amente S. Targeting the 8-oxodG Base Excision Repair Pathway for Cancer Therapy. Cells. 2025; 14(2):112. https://doi.org/10.3390/cells14020112

Chicago/Turabian Style

Piscone, Anna, Francesca Gorini, Susanna Ambrosio, Anna Noviello, Giovanni Scala, Barbara Majello, and Stefano Amente. 2025. "Targeting the 8-oxodG Base Excision Repair Pathway for Cancer Therapy" Cells 14, no. 2: 112. https://doi.org/10.3390/cells14020112

APA Style

Piscone, A., Gorini, F., Ambrosio, S., Noviello, A., Scala, G., Majello, B., & Amente, S. (2025). Targeting the 8-oxodG Base Excision Repair Pathway for Cancer Therapy. Cells, 14(2), 112. https://doi.org/10.3390/cells14020112

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Targeting the 8-oxodG Base Excision Repair Pathway for Cancer Therapy

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI